Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
That's the drug.
So Adacanimab uh was transformed in a in a rather dark baptism, I think, from Ajucanimab into Ajuhelm for the treatment of Alzheimer's disease.
Oh, we've been treating mice successfully with anti-amyloid therapeutics since the turn of the century.
Uh in fact that was the breakthrough study that even uh in mice that even made the national news that was so provocative.
Since then, these drugs in the class have been pretty good at removing amyloid.
In fact, with with respect to adjucamab, the two thousand sixteen front cover of nature.
depicted a b uh brain with and without amyloid and the story was Adycanamab's ability in an early phase study to remove amyloid.
So that's been well described for this particular drug for at least four or five years.
No surprise there.
We knew that.
The question was
the degree to which this removal of amyloid translated into improvements in in or stabilization in the health and well being of our patient's brain.
And I think there I'm of the view
that more study is was still is needed of this drug in simply put
This drug is not ready for a p to be given to patients with a prescription, but to be given to subjects based having reviewed in an informed consent form.
I still think the drug needs more study.
Uh I'm of the view that there may be something here.
Uh we can talk more what that may be and why.
Um but but the removal of amyloid was not a surprise.
We knew that for five years.
Showing 801–820 of 1,378 · page 41 of 69
← Previous
Next →